{"id":10637,"date":"2011-08-04T16:10:45","date_gmt":"2011-08-04T20:10:45","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&p=10637"},"modified":"2011-08-04T16:10:45","modified_gmt":"2011-08-04T20:10:45","slug":"yale-receives-2-5-million-from-medtronic-for-independent-evaluation-of-rhbmp-2","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/08\/04\/yale-receives-2-5-million-from-medtronic-for-independent-evaluation-of-rhbmp-2\/","title":{"rendered":"Yale Receives $2.5 Million from Medtronic for Independent Evaluation of rhBMP-2"},"content":{"rendered":"

Responding to intense criticism from the government, the press, and the academic community, Medtronic announced<\/a> that it was giving $2.5 million to Yale researchers to oversee independent reviews of the safety and effectiveness of rhBMP-2 (Infuse). Criticism of the spinal growth product was the sole topic of the June issue of the Spine Journal<\/em><\/a>. Yale’s Harlan Krumholz (editor-in-chief of CardioExchange) will assemble a steering committee of 12 to 15 advisers and will commission two independent clinical research organizations to conduct the analyses.<\/p>\n

Furthermore, Medtronic said it would place rhBMP-2’s clinical trial data on the ClinicalTrials.Gov website, including data from trials completed before September 2007, when publication on the site became mandatory. In addition, Krumholz will spearhead a novel initiative that will provide researchers with access to the complete patient-level data from clinical trials of the drug.<\/p>\n

You can read more about the announcement in the Wall Street Journal<\/em><\/a>, the <\/a>New York Times<\/a>,<\/em> and the Milwaukee Journal Sentinel<\/em>.<\/a><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Responding to intense criticism from the government, the press, and the academic community, Medtronic announced that it was giving $2.5 million to Yale researchers to oversee independent reviews of the safety and effectiveness of rhBMP-2 (Infuse). Criticism of the spinal growth product was the sole topic of the June issue of the Spine Journal. Yale’s […]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[937,936],"class_list":["post-10637","post","type-post","status-publish","format-standard","hentry","category-general","tag-infuse","tag-rhbmp-2"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/10637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=10637"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/10637\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=10637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=10637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=10637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}